Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131767 | 0.82 | ACHE (0.37) | ACHEDAOTSHR | |
| SCHEMBL1125635 | 0.78 | ALDH1A1 (0.40) | ACHEALDH1A1POLBTSHRHTT | |
| SCHEMBL667921 | 0.78 | CES2 (0.36) | — | |
| Bromide SCHEMBL733561 | 0.76 | CES2 (0.34) | — | |
| SCHEMBL19031830 | 0.73 | HDAC1 (0.35) | HDAC1HDAC6 | |
| SCHEMBL29995043 | 0.73 | RAPGEF4 (0.34) | KMT2AMAPTMEN1KMO | |
| SCHEMBL1138476 | 0.73 | CYP3A4 (0.46) | ALDH1A1MAPT | |
| SCHEMBL666611 | 0.73 | RAPGEF4 (0.34) | KMT2AMAPTMEN1KMO | |
| SCHEMBL929959 | 0.72 | RAB9A (0.46) | KMT2AALDH1A1MEN1HTT | |
| SCHEMBL30883901 | 0.72 | RAB9A (0.46) | KMT2AALDH1A1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| WO-2025106383-A1 | PYRROLIDINYL DERIVATIVES USEFUL AS HCN1/HCN 2 MODULATORS | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250042934-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-11945836-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20210017218-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS INC (US) | 2021-01-21 | — | — | US | disclosed |
| EP-3719029-A1 | COMPOSITIONS FOR INDUCING SEDATION | Sage Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| US-10774108-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| WO-2002002565-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 2002-01-10 | — | — | WO | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1053239-A1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 2000-11-22 | — | — | EP | disclosed |
| EP-1007515-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | Abbott Laboratories (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-1999041256-A1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999010331-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945836-B2 | Compositions and methods for treating CNS disorders | GRIN2B, ADRA2B, ADRA1B | HDAC1 932/4885HDAC6 709/4885ACHE 188/4885 |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | HDAC1 932/4885HDAC6 709/4885ACHE 188/4885 |
| US-20210017218-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | HDAC1 932/4885HDAC6 709/4885ACHE 188/4885 |
| US-10774108-B2 | Compositions and methods for treating CNS disorders | GRIN2B, ADRA2B, ADRA1B | HDAC1 932/4885HDAC6 709/4885ACHE 188/4885 |
| US-20250042934-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | HDAC1 932/4885HDAC6 709/4885ACHE 188/4885 |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | HDAC1 116/4885HDAC6 419/4885ACHE 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.